STAFFORD, Texas — August 11, 2025 — Leads & Copy — Greenwich LifeSciences Inc. (Nasdaq: GLSI), a biopharmaceutical company focused on GLSI-100 development, shared an update on CEO interviews and corporate events. Videos, including CEO interviews, are on the company website.
Recent events include the Jefferies London Healthcare Conference (Nov 19-21, 2024), the San Antonio Breast Cancer Symposium (Dec 10-13, 2024), the Annual Meeting of Stockholders (Dec 19, 2024), the BIO CEO & Investor Conference (Feb 10-11, 2025), the German Breast Group Annual Scientific Meeting (Mar 6-7, 2025), the ESMO Breast Conference in Germany (May 14-16, 2025), the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq (May 20, 2025), the American Society of Clinical Oncology (ASCO) (Jun 2, 2025), the Noble Emerging Growth Virtual Conference (Jun 4, 2025), the Jefferies Global Healthcare Conference (Jun 5, 2025), and the BIO International Convention (Jun 16-19, 2025).
FLAMINGO-01 (NCT05232916) is a Phase III trial evaluating GLSI-100 safety and efficacy in HER2 positive breast cancer patients, led by Baylor College of Medicine with US and European sites. It plans to open 150 sites globally.
One in eight U.S. women develop invasive breast cancer, with 300,000 new patients and 4 million survivors. HER2 is expressed in 75% of breast cancers.
Greenwich LifeSciences focuses on GP2 development, an immunotherapy to prevent breast cancer recurrences, and has started the Phase III FLAMINGO-01 trial.
Snehal Patel, Investor Relations, can be reached at (832) 819-3232 or info@greenwichlifesciences.com. Dave Gentry, RedChip Companies Inc., can be reached at 1-800-RED CHIP (733 2447) or dave@redchip.com
For more information on FLAMINGO-01, please visit the Company’s website and clinicaltrials.gov. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com
Source: Greenwich LifeSciences, Inc.
